Use of convalescent plasma in COVID-19 patients with immunosuppression

Jonathon W. Senefeld1 | Stephen A. Klassen1 | Shane K. Ford1 | Katherine A. Senese1 | Chad C. Wiggins1 | Bruce C. Bostrom2 | Michael A. Thompson3 | Sarah E. Baker1 | Wayne T. Nicholson1 | Patrick W. Johnson4 | Rickey E. Carter4 | Jeffrey P. Henderson5 | William R. Hartman6 | Liise-anne Pirofski7 | R. Scott Wright8 | De Lisa Fairweather9 | Katelyn A. Bruno9 | Nigel S. Paneth10 | Arturo Casadevall11 | Michael J. Joyner1

1Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA
2Pediatric Oncology and Hematology, Children's Hospital of Minnesota, Minneapolis, Minnesota, USA
3Aurora Cancer Care, Advocate Aurora Health, Milwaukee, Wisconsin, USA
4Department of Health Sciences Research, Mayo Clinic, Jacksonville, Florida, USA
5Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA
6Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA
7Division of Infectious Diseases, Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, USA
8Department of Cardiovascular Medicine and Director Human Research Protection Program, Mayo Clinic, Rochester, Minnesota, USA
9Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, Florida, USA
10Department of Epidemiology and Biostatistics and Department of Pediatrics and Human Development, Michigan State University, East Lansing, Michigan, USA
11Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA

Correspondence
Michael J. Joyner, Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Email: joyner.michael@mayo.edu

Funding information
Natural Sciences and Engineering Research Council of Canada, Grant/Award Number: PDF-532926-2019; National Heart, Lung, and Blood Institute, Grant/Award Numbers: 5R35HL139854, F32HL154320, R01HL059842

Abstract
In the absence of effective countermeasures, human convalescent plasma has been widely used to treat severe acute respiratory syndrome coronavirus 2, the causative agent of novel coronavirus disease 19 (COVID-19), including among patients with innate or acquired immunosuppression. However, the association between COVID-19-associated mortality in patients with immunosuppression and therapeutic use of convalescent plasma is unknown. We review 75 reports, including one large matched-control registry study of 143 COVID-19 patients with hematological malignancies, and 51 case reports and 23 case series representing 238 COVID-19 patients with immunosuppression. We review clinical features and treatment protocols of COVID-19 patients with immunosuppression.

Received: 19 February 2021 Revised: 5 May 2021 Accepted: 5 May 2021
DOI: 10.1111/trf.16525
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2021 The Authors. Transfusion published by Wiley Periodicals LLC. on behalf of AABB.

Transfusion. 2021;1–9.
after treatment with human convalescent plasma. We also discuss the time course and clinical features of recovery. The available data from case reports and case series provide evidence suggesting a mortality benefit and rapid clinical improvement in patients with several forms of immunosuppression following COVID-19 convalescent plasma transfusion. The utility of convalescent plasma or other forms of antibody therapy in immune-deficient and immune-suppressed patients with COVID-19 warrants further investigation.

**KEYWORDS**
FFP transfusion, transplantation—solid organ, transfusion practices (oncology–hematology)

---

**1 | INTRODUCTION**

Convalescent plasma is a passive antibody therapy that has been used to prevent or treat infectious diseases for more than a century. In the absence of effective countermeasures, human convalescent plasma has been widely used to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of novel coronavirus disease 19 (COVID-19). Convalescent plasma has received full or conditional regulatory authorization in the United States and many other countries for therapeutic use in adults and children hospitalized with suspected or laboratory-confirmed SARS-CoV-2 positive COVID-19. The evidence supporting the use of convalescent plasma to treat patients with COVID-19 is not definitive. There is evidence that supports the therapeutic use of convalescent plasma among patients with COVID-19 who are treated earlier in the disease course using plasma with sufficient antibody levels. In contrast, however, several large clinical trials that transfused severely ill patients later in the disease course have suggested there is no mortality benefit conferred from COVID-19 convalescent plasma.

Although there are many studies evaluating the clinical efficacy of convalescent plasma in otherwise immunocompetent patients, there is a paucity of studies evaluating the use of convalescent plasma in COVID-19 patients with immunosuppression or immunodeficiency. Patients with immunosuppression or immunodeficiency have been disproportionately affected by the COVID-19 pandemic, and often present with persistent SARS-CoV-2 infection and may shed viable SARS-CoV-2 for months. In this context, we summarize the growing number of contemporary case reports and case series of the clinical experiences of COVID-19 patients with primary and secondary immunosuppression who were treated with specific neutralizing antibodies via COVID-19 convalescent plasma transfusion. Importantly, evaluation of the clinical responses to convalescent plasma transfusion in immunosuppressed patients who cannot generate innate immune responses may provide an optimal opportunity to assess the effect of convalescent plasma per se.

**2 | METHODS**

We included investigations of the impact of human convalescent plasma therapy on COVID-19 patient mortality in patients with primary or secondary immunosuppression, which included case series, case reports, and media reports in lay press. References for this review were identified through searches of the online PubMed and MEDLINE databases for articles published from January 1, 2020 to April 10, 2021. Keywords used in the search included: (convalescent plasma or convalescent serum) AND COVID-19 (and Medical Subject Headings terms; MeSH terms). During review of abstracts, additional keywords used to search for relevant articles included: immunosuppressed, immunocompromised, immunodeficient, cancer, transplant, malignancy, and agammaglobulinemia. Relevant articles and data were also identified through non-systematic searches in Google Scholar and medRxiv. Articles resulting from these searches and relevant references cited in those articles were examined.

To be considered eligible for inclusion, studies must have: (1) included hospitalized patients with primary or secondary immunosuppression and a confirmed diagnosis of COVID-19, (2) used convalescent plasma as a COVID-19 treatment, and (3) reported patient mortality. Using an a posteriori approach, studies were further restricted to include only the following: (1) hypogammaglobulinemia or x-linked agammaglobulinemia, (2) common variable immune deficiency, (3) hematological malignancy, or (4) solid organ transplants. Although our search yielded articles describing use of COVID-19 convalescent plasma in the context of other potentially relevant conditions (myasthenia gravis, trisomy 21, and trisomy 21,23)
Sjögrens syndrome, hemodialysis, and rheumatoid arthritis, there were very few represented patient cases, thus, our a posteriori restriction provided more robust evidence on fewer cohorts of patients. Two reviewers (J.W.S and S.A.K.) independently screened the titles and abstracts of all studies identified by the search to determine eligibility. Studies that were deemed potentially eligible had their full text reviewed (J.W.S and S.A.K.) to determine if they met the criteria for inclusion in the review. Disagreement was resolved by consensus. Three reviewers (J.W.S, S.A.K., and S.K.F.) extracted study and patient characteristics as well as clinical information, and extracted data were independently reviewed (K.A.S.). All procedures accessed public information and did not require ethical review as determined by the Mayo Clinic Institutional Review Board in accordance with the Code of Federal Regulations, 45 CFR 46.102, and the Declaration of Helsinki.

Disease severity of COVID-19 was delineated using a six-level ordinal scale, with higher scores indicating more progressed clinical course of COVID-19 at the time of convalescent plasma transfusion. Scores on the ordinal scale were defined as follows: a score of 1 indicated not hospitalized; 2, hospitalized and not receiving supplemental oxygen; 3, hospitalized and receiving supplemental oxygen; 4, hospitalized and receiving oxygen supplementation administered by a high-flow nasal cannula or noninvasive ventilation; 5, hospitalized and receiving extracorporeal membrane oxygenation or invasive mechanical ventilation; and 6, death.

In all studies but one large matched-control study, there were no appropriate and comparable control groups. Thus, no analytical statistics analyses were performed, and no novel measures of probability are reported. Descriptive statistics are presented as frequencies and percentages based on numerical values reported in primary literature. These descriptive statistics should not be used to infer definitive treatment effects.

2.1 Aggregate results

The literature search yielded 831 reports, of which 75 reports met the eligibility criteria and were included in the systematic review (Figure 1). This review includes one large matched-control registry study of 143 patients with hematological malignancies, and 51 case reports and 23 case series reporting 238 COVID-19 patients with primary immunosuppression due to Agammaglobulinemia (X-linked or autosomal) or Common Variable Immunodeficiency, and secondary immunosuppression related to hematological malignancies and solid organ transplants who were transfused with convalescent plasma. A summary overview of patient characteristics, COVID-19 therapies used (including convalescent plasma), and clinical symptomology of these patients is available as Tables S1–S3. Mortality among these hospitalized COVID-19 patients with immunosuppression who were treated with convalescent plasma was 16% (60 of 381 patients) with ~60% of patients demonstrating rapid clinical improvement within 5 days of convalescent plasma therapy, see Table 1.

3 PRIMARY IMMUNODEFICIENCY

3.1 Agammaglobulinemia

Patients with Agammaglobulinemia do not produce endogenous antibodies and require regular intravenous infusions or subcutaneous injections of immunoglobulins to avoid serial infections from common pathogens. However, immunoglobulin replacement therapy cannot protect immunosuppressed patients against pathogens for which antibodies are uncommon or absent in the immunoglobulin donor pool, such as the SARS-CoV-2 virus. We identified 15 patients from six case reports and three case series. The COVID-19 patients with agammaglobulinemia were predominantly male and primarily young to middle-aged (range, 3–40 years). These patients also had a wide range of disease severity (range, 2–5) assessed using a six-level ordinal scale to assess the clinical course of COVID-19. Overall, the observed mortality rate was 7% (1 of 15 patients) and rapid improvement in supplemental oxygen was observed in three of six patients (50%) that reported on these metrics. In a case series, three male patients with X-linked Agammaglobulinemia (aged 10, 24 and 40 years) with prolonged COVID-19 who required oxygen support were treated with
broad-spectrum antibiotics with limited or no clinical improvement. Each patient then received convalescent plasma, resulting in rapid clinical improvement in all three patients and hospital discharge within 72 hours for the two adult patients.

3.2 | Common variable immunodeficiency

Common variable immunodeficiency represents a heterogeneous collection of immunodeficiencies commonly characterized by intrinsic B-cell defects and suppressed antibody production. Patients with common variable immunodeficiency often present with inflammatory and autoimmune disorders, which are suspected to elevate patient risk for progression to severe COVID-19. We identified seven patients with common variable immunodeficiency from three case reports and one case series. Among these seven patients, ∼50% were female, ∼50% were receiving mechanical ventilation or extracorporeal membrane oxygenation, and one mortality was observed. In the case series, four patients with antibody-deficient common variable immunodeficiency diagnosed with severe or life-threatening COVID-19 were transfused with convalescent plasma for COVID-19 therapy. Three of these patients survived following convalescent plasma transfusion, including two patients whose clinical symptomatology required mechanical ventilation or extracorporeal membrane oxygenation. In two case studies of a young male (37 years) and young female (25 years) who had life-threatening COVID-19 which required mechanical ventilation or extracorporeal membrane oxygenation, both patients demonstrated rapid clinical improvement resulting in successful weaning from invasive ventilation within 48 h.

These data from patients with primary immunodeficiencies suggest that COVID-19 convalescent plasma could be a valuable therapeutic approach, but further studies should be performed to determine the therapeutic outcomes of convalescent plasma transfusion in patients with abnormal capacity to produce antibody responses.

4 | SECONDARY IMMUNODEFICIENCY

4.1 | Hematological malignancy

Hematological malignancies are associated with deficits in both humoral and cellular immunity which may contribute to increased risk of progression to severe COVID-19. Many treatments of hematologic malignancies, such as the cornerstone of treatment (anti-CD-20 monoclonal antibodies), may lead to prolonged B-cell depletion and impaired immune responses. From 32 case reports and 11 case series, we identified 150 COVID-19 patients with hematological malignancies treated with convalescent plasma. Among these 150 patients, the mortality rate was 20% (30 of 150 patients), 37 patients demonstrated rapid clinical improvement after convalescent plasma transfusion, and the average time between convalescent plasma transfusion and hospital discharge was 27 days. In a case series, 17 patients with B-cell lymphopenia and protracted COVID-19 received convalescent plasma with high neutralizing antibody titers. Although patients received plasma late in the
disease course (7–83 days after symptom onset), 16 patients demonstrated improvement of clinical symptoms and reduction in SARS-CoV-2 RNAemia within 7–14 days. One patient, who required mechanical ventilation, died. Similarly, in a separate cohort of 14 patients with hematological malignancies, most patients exhibited improvement in clinical symptomatology, including reduced oxygen requirements, after treatment with convalescent plasma. Notably, a patient with protracted COVID-19, evidenced by three separate COVID-19-related hospitalizations over a 100+ day period, and with lymphoma-associated B-cell immunodeficiency demonstrated rapid reductions in fever, oxygen requirements, and lung infiltrates (via chest computed tomography) forthwith after two separate convalescent plasma transfusions separated by ~90 days.

At the time of writing, there is one large matched-control study using registry data from the COVID-19 and Cancer Consortium (CCC19) international consortium. The 30-day mortality was evaluated in hospitalized adults with hematologic malignancy and COVID-19, comparing 143 patients transfused with convalescent plasma and 823 matched controls who received standard care treatment. Death within 30 days occurred in 13.3% (19 of 143 patients) in the patients transfused with convalescent plasma and 24.8% (204 of 823 patients) in the matched control group. Among these patients with hematologic malignancy, convalescent plasma treatment was associated with a lower risk of death after adjustment for potential confounding factors (hazard ratio, 0.60; 95% confidence interval [CI], 0.37–0.97) or after propensity-score matching (hazard ratio, 0.52; 95% CI, 0.29–0.92). Although these data are consistent with a mortality benefit associated with administration of COVID-19 convalescent plasma in the context of hematological malignancy, this observational study should not be inferred for causality.

### 4.2 | Solid organ transplant

Recipients of solid organ transplants are known to be vulnerable to viral infections secondary to a weakened T-cell mediated immune response. From 10 case reports and 10 case series, we identified 66 COVID-19 patients who received a solid organ transplant and who were treated with convalescent plasma. Of these 66 patients, mortality was observed in nine patients (14%), 4 patients remain hospitalized at the end of the observation period, and 25 patients demonstrated rapid improvement in clinical symptomatology. In a case series, 13 hospitalized patients with COVID-19 who were solid organ transplant recipients were transfused with two units of convalescent plasma and received concomitant therapies, primarily broad spectrum antibiotics and hydroxychloroquine. Nine patients were discharged home without readmission, of which eight had de-escalating oxygen support within 7 days of plasma transfusion. One patient had a prolonged hospital admission and three patients died. Of the three patients who expired, two patients received plasma more than 2 weeks after symptom onset—a timeframe which may be associated with a reduced mortality benefit of COVID-19 convalescent plasma. These data are consistent with a recent systematic review of clinical outcomes of COVID-19 among solid organ transplant recipients.

### 5 | CONCLUSIONS

The available data from case reports and case series provide evidence suggesting a mortality benefit and rapid clinical improvement in patients with several forms of immunosuppression following COVID-19 convalescent plasma transfusion. In contrast to ongoing studies of convalescent plasma efficacy in clinical trials where the majority of patients are otherwise immunocompetent and thus mount their own protective antibody responses, convalescent plasma use in immunosuppressed patients represents a situation where exogenous antibody is given in the setting of an immune deficit. However, there is some hesitancy about using convalescent plasma due to concern that it could select for the emergence of SARS-CoV-2 variants, given reports that new SARS-CoV-2 variants were found in a COVID-19 patient with immunosuppression treated with plasma. As described elsewhere, it is highly unlikely that convalescent plasma is the source of SARS-CoV-2 variants currently circulating, rather these variants were more likely selected by natural immune responses in infected patients and convalescent plasma may be one of few potential therapeutics for emerging SARS-CoV-2 variants.

The case series and case reports summarized here provide evidence suggesting a mortality benefit and rapid clinical improvement in patients with several forms of immunosuppression following COVID-19 convalescent plasma transfusion. These findings were an important component of the scientific evidence considered by the US Food and Drug Administration suggesting a longer potential therapeutic window for COVID-19 convalescent plasma among immunosuppressed or immunodeficient patients than is evident in immunocompetent patients. Although these summary findings are encouraging for the use of therapeutic convalescent plasma in COVID-19 patients with immunosuppression, well-controlled, published data in these populations remain lacking, including
only one large matched treatment-control study\textsuperscript{29} and no randomized controlled trials. As such, the data should not be used to infer definitive treatment effects. The utility of convalescent plasma or other forms of antibody therapy in immunosuppressed or immunodeficient patients with COVID-19 warrants further investigation.

**ACKNOWLEDGMENTS**

This research was supported, in part, by National Heart, Lung, and Blood Institute (F32HL154320 to JWS; 5R35HL139854 to MJJ; RO1 HL059842 to AC) and Natural Sciences and Engineering Research Council of Canada (PDF-532926-2019 to SAK).

**CONFLICT OF INTEREST**

The authors have disclosed no conflicts of interest.

**ORCID**

Jonathon W. Senefeld \(\text{https://orcid.org/0000-0001-8116-3538}\)

William R. Hartman \(\text{https://orcid.org/0000-0003-2118-7591}\)

**REFERENCES**

1. Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020;130:1545–8.
2. Ripoll JG, van Helmond N, Senefeld JW, Wiggins CC, Klassen SA, Baker SE, et al. Convalescent plasma for infectious diseases: historical framework and use in COVID-19. Clin Microbiol NewsL. 2021;43:23–32.
3. Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;130:2757–65.
4. US Food and Drug Administration. Clinical memorandum for the emergency use authorization of COVID-19 convalescent plasma, 2020.
5. Klassen SA, Senefeld JW, Johnson PW, Carter RE, Wiggins CC, Shoham S, et al. The effect of convalescent plasma therapy on mortality among patients with COVID-19: Systematic review and meta-analysis. Mayo Clin Proc. 2021;96(5):1262–1275. \(\text{https://doi.org/10.1016/j.mayocp.2021.02.008}\).
6. Salazar E, Christensen PA, Graviss EA, Nguyen DT, Castillo B, Chen J, et al. Significantly decreased mortality in a large cohort of coronavirus disease 2019 (COVID-19) patients transfused early with convalescent plasma containing high-titer anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein IgG. Am J Pathol. 2021;191:90–107.
7. Salazar E, Perez KK, Ashraf M, Chen J, Castillo B, Christensen PA, et al. Treatment of coronavirus disease 2019 (COVID-19) patients with convalescent plasma. Am J Pathol. 2020;190:1680–90.
8. Rasheed AM, Fatak DF, Hashim HA, Maulood MF, Kahah KK, Almusawi YA, et al. The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq. Infez Med. 2020;28:357–66.
9. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020;117:9490–6.
10. Hegerova L, Gooley TA, Sweerus KA, Maree C, Bailey N, Bailey M, et al. Use of convalescent plasma in hospitalized patients with COVID-19: case series. Blood. 2020;136:759–62.
11. Zeng QL, Yu ZJ, Gou JJ, Li GM, Ma SH, Zhang GF, et al. Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019. J Infect Dis. 2020;222:38–43.
12. Xia X, Li K, Wu L, Wang Z, Zhu M, Huang B, et al. Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion. Blood. 2020;136:755–9.
13. Abolghasemi H, Eshghi P, Cheraghali AM, Imani Fooladi AA, Bolouki Moghaddam F, Imaznadeh S, et al. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study. Transfus Apher Sci. 2020;59:102875.
14. Rogers R, Shehadeh F, Mylona EK, Rich J, Neill M, Touzard-Romo F, et al. Convalescent plasma for patients with severe COVID-19: a matched cohort study. Clin Infect Dis. 2020.
15. Altuntas F, Aya N, Yigenoglu TN, Basi S, Dal MS, Korkmaz S, et al. Convalescent plasma therapy in patients with COVID-19. Transfus Apher Sci. 2020;60:102955.
16. Horby PW, Estcourt L, Peto L, Emberson JR, Staplin N, Spata E, et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv. 2021. \(\text{https://doi.org/10.1101/2021.03.09.21252736}\).
17. Simonovich VA, Burgos Pratx LD, Scibona P, Beruto MV, Vallone MG, Vazquez C, et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. N Engl J Med. 2021;384:619–29.
18. Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW, et al. Convalescent plasma antibody levels and the risk of death from Covid-19. N Engl J Med. 2021;384(11):1015–1027.
19. Libster R, Perez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med. 2021;384(7):610–618.
20. Rosenbaum L. The untold toll—the Pandemic’s effects on patients without Covid-19. N Engl J Med. 2020;382:2368–71.
21. Aydillo T, Gonzalez-Reiche AS, Aslam S, de Guichite A, Khan Z, Obla A, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med. 2020;383:2586–8.
22. Aksoy E, Oztutan T. COVID-19 presentation in association with myasthenia gravis: a case report and review of the literature. Case Rep Infect Dis. 2020;2020:8845844.
23. Rodriguez Z, Shang AL, Verkerke H, Lough C, Zimmerman MG, Suthar M, et al. COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease. Blood Adv. 2020;4:4278–81.
24. Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol. 2020;92:1890–901.
25. Lindemann M, Krawczyk A, Dolff S, Konik M, Rohn H, Platte M, et al. SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma. J Med Virol. 2021;93:3047–54.

26. Gerber V, Velay A, Boehn L, Solis M, Kaeuffer C, Rougier E, et al. Protracted SARS-CoV-2 pneumonia with rituximab treatment: about two cases. J Med Virol. 2021;93(7):4141–4144.

27. Kenig A, Ishay Y, Kharouf F, Rubin L. Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based depleted products. Clin Immunol. 2021;227:108723.

28. Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med. 2020;383:2041–52.

29. Thompson MA, Henderson JP, Shah PK, Rubinstein SM, Joyner MJ, Choueiri TK, et al. Convalescent plasma and improved survival in patients with hematologic malignancies and COVID-19. medRxiv. 2021. https://doi.org/10.1101/2021.02.05.21250953.

30. El-Bohy M, Poowuttikul P, Secord E. Humoral immune deficiencies of childhood. Pediatr Clin North Am. 2019;66:897–903.

31. Mira E, Yarce OA, Ortega C, Fernandez S, Pascual NM, El-Bohy M, Poowuttikul P, Secord E. Humoral immune deficiencies of childhood. Pediatr Clin North Am. 2019;66:897–903.

32. Mira E, Yarce OA, Ortega C, Fernandez S, Pascual NM, El-Bohy M, Poowuttikul P, Secord E. Humoral immune deficiencies of childhood. Pediatr Clin North Am. 2019;66:897–903.

33. Iaboni A, Wong N, Betschel SD. A patient with X-linked agammaglobulinemia and COVID-19. Impartial Reporter 2020.

34. Hovey JG, Tolbert D, Howell D. Burton's agammaglobulinemia: diagnosis, management, and treatment. Immunol Allergy Clin North Am. 2015;35:637–58.

35. Van Damme KFA, Tavernier S, Van Roy N, De Leeuw E, Declercq J, Bosteels C, et al. Case report: convalescent plasma, a targeted therapy for patients with COVID-19. Front Immunol. 2020;11:396761.

36. Ribeiro LC, Benites BD, Ulaf RG, Nunes TA, Costa-Lima C, Addas-Carvalho M, et al. Rapid clinical recovery of a SARS-CoV-2 infected common variable immunodeficiency patient following the infusion of COVID-19 convalescent plasma. Allergy Asthma Clin Immunol. 2021;17:14.

37. Jin H, Reed JC, Liu STH, Ho HE, Lopes JP, Ramsey NB, et al. Protracted SARS-CoV-2 pneumonia with rituximab treatment: about two cases. J Med Virol. 2021;93(7):4141–4144.

38. Senefeld ET, Alkhatib G, Quinti I, Neven B, Fischer A, Seoane E, et al. Coronavirus disease 2019 in patients with inborn errors of immunity: an international study. J Allergy Clin Immunol. 2021;147(2):520–526.
57. Malsy J, Veletzky L, Heide J, Hennigs A, Gil-Ibanez I, Stein A, et al. Sustained response after remdesivir and convalescent plasma therapy in a B-cell depleted patient with protracted COVID-19. Clin Infect Dis. 2020.

58. Moore JL, Ganapathiraju PV, Kurtz CP, Waincoat B. A 63-year-old woman with a history of non-Hodgkin lymphoma with persistent SARS-CoV-2 infection who was seronegative and treated with convalescent plasma. Am J Case Rep. 2020;21:e927812.

59. Niu A, McDougal A, Ning B, Safa F, Luk A, Mushatt DM, et al. COVID-19 in allogeneic stem cell transplant: high false-negativity and role of CRISPR and convalescent plasma. Bone Marrow Transplant. 2020;55:2354–6.

60. Rodriguez JA, Bonnano C, Khatiwada P, Roa AA, Mayer D, Eckardt PA. COVID-19 coinfection with mycobacterium abscessus in a patient with multiple myeloma. Case Rep Infect Dis. 2021;2021:8840536.

61. Shankar R, Radhakrishnan N, Dua S, Arora S, Rana M, Sahu DK, et al. Convalescent plasma to aid in recovery of COVID-19 pneumonia in a child with acute lymphoblastic leukemia. Transfus Apher Sci. 2021;60(1):102956.

62. Wang B, Van Oekelen O, Mouhieddine TH, Del Valle DM, Richter J, Cho HJ, et al. A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. J Hematol Oncol. 2020;13:94.

63. Wright Z, Bersabe A, Eden R, Cap A. Successful use of COVID-19 convalescent plasma in a patient recently treated for follicular lymphoma. Clin Lymphoma Myeloma Leuk. 2021;21(1):66–68.

64. Zhang LL, Liu Y, Guo YG, Chang J, Gao B, Li ZZ, et al. Convalescent plasma rescued a severe COVID-19 patient with chronic myeloid leukemia blast crisis and myelofibrosis. Turk J Haematol. 2021;18(1):74–76.

65. Kasik V. Cancer patient who caught COVID-19 recovered with immune plasma treatment News Splitter, 2020.

66. Hughes CM, Gregory GP, Pierce AB, Druce JD, Catton M, Chong B, et al. Clinical illness with viable SARS-CoV-2 virus presenting 72 days after infection in an immunocompromised patient. Infect Control Hosp Epidemiol. 2021;1:1–12.

67. Kemp SA, Collier DA, Datir RP, Ferreira I, Gayed S, Jahan A, et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature. 2021;592:277–82.

68. Khan AM, Ajmal Z, Raval M, Tobin E. Concurrent diagnosis of acute myeloid leukemia and COVID-19: a management challenge. Cureus. 2020;12:e9629.

69. Khatamzas E, Rehn A, Muenchhoff M, Hellmuth J, Gaitzsch E, Weiglein T, et al. Emergence of multiple SARS-CoV-2 mutations in an immunocompromised host. medRxiv. 2021. https://doi.org/10.1101/2021.01.01.20248871.

70. Martinot M, Jary A, Fafi-Kremer S, Leducq V, Delagreverie H, Garnier M, et al. Remdesivir failure with SARS-CoV-2 RNA-dependent RNA-polymerase mutation in a B-cell immunodeficient patient with protracted Covid-19. Clin Infect Dis. 2020.

71. McKemey E, Shields AM, Faustini SE, Hill HJ, Barnskaya A, Stamatakis Z, et al. Resolution of persistent COVID-19 after convalescent plasma in a patient with B cell aplasia. J Clin Immunol. 2021.
85. Delgado-Fernandez M, Garcia-Gemar GM, Fuentes-Lopez A, Munoz-Perez MI, Oyonarte-Gomez S, Ruiz-Garcia I, et al. Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency—three consecutive cases and review of the literature. Enferm Infec Microbiol Clin. 2021.
86. Raja MA, Mendoza MA, Villavicencio A, Anjan S, Reynolds JM, Kittipibul V, et al. COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis of current literature. Transplant Rev. 2020;35:100588.
87. Antony SJ, Singh J, de Jesus M, Lance J. Early use of tocilizumab in respiratory failure associated with acute COVID-19 pneumonia in recipients with solid organ transplantation. IDCases. 2020;21:e00888.
88. Choudhury A, Reddy GS, Venishetty S, Pamecha V, Shasthry SM, Tomar A, et al. COVID-19 in liver transplant recipients—a series with successful recovery. J Clin Transl Hepatol. 2020;8:467–73.
89. Christensen J, Kumar D, Moinuddin I, Bryson A, Kashi Z, Kimball P, et al. Coronavirus disease 2019 viremia, Serologies, and clinical course in a case series of transplant recipients. Transplant Proc. 2020;52:2637–41.
90. Jamir I, Lohia P, Pandke RK, Setia R, Singhal AK, Chaudhary A. Convalescent plasma therapy and remdesivir duo successfully salvaged an early liver transplant recipient with severe COVID-19 pneumonia. Ann Hepatobiliary Pancreat Surg. 2020;24:526–32.
91. Jiang J, Miao Y, Zhao Y, Lu X, Zhou P, Zhou X, et al. Convalescent plasma therapy: helpful treatment of COVID-19 in a kidney transplant recipient presenting with serve clinical manifestation and complex complications. Clin Transplant. 2020;34:e14025.
92. Trimarchi H, Gianserra R, Lampo M, Monkowski M, Lodolo J. Eculizumab, SARS-CoV-2 and atypical hemolytic uremic syndrome. Clin Kidney J. 2020;13:739–41.
93. Yi SG, Rogers AW, Saharia A, Aoun M, Faour R, Abdelrahim M, et al. Early experience with COVID-19 and solid organ transplantation at a US high-volume transplant center. Transplantation. 2020;104:2208–14.
94. Bartosch J. Lung transplant patient with COVID-19 recovers following plasma clinical trial. Chicago, IL: The University of Chicago Medicine; 2020.
95. 59 WMaF. Plasma donation helps save Indiana man diagnosed with COVID-19, 2020.
96. Transplant NBA. One of the first COVID-19 convalescent plasma recipients supports donor appeal. Give Blood. 2020.
97. Rahman F, Liu STH, Taimur S, Jacobs S, Sullivan T, Dunn D, et al. Treatment with convalescent plasma in solid organ transplant recipients with COVID-19: experience at large transplant center in New York City. Clin Transplant. 2020;34:e14089.
98. Fung M, Nambiar A, Pandey S, Aldrich JM, Teraoka J, Freise C, et al. Treatment of immunocompromised COVID-19 patients with convalescent plasma. Transpl Infect Dis. 2020;23:e13477.
99. Katz-Greenberg G, Yadav A, Gupta M, Martinez-Cantarín GM, Gulati R, Ackerman L, et al. Outcomes of COVID-19-positive kidney transplant recipients: a single-center experience. Clin Nephrol. 2020;94:318–21.
100. Naeem S, Gohh R, Bayliss G, Cosgrove C, Farmakiotis D, Merhi B, et al. Successful recovery from COVID-19 in three kidney transplant recipients who received convalescent plasma therapy. Transpl Infect Dis. 2020;22:e13382.
101. Lima B, Gibson GT, Vallilanghi S, Malhamé K, Maybaum S, Hussain ST, et al. COVID-19 in recent heart transplant recipients: clinicopathologic features and early outcomes. Transpl Infect Dis. 2020;22:e13382.
102. Mehta SA, Rana MM, Motter JD, Small CB, Pereira MR, Stosor V, et al. Incidence and outcomes of COVID-19 in kidney and liver transplant recipients with HIV: report from the national HOPE in action consortium. Transplantation. 2021;105:216–24.
103. Kutzler HL, Poulos CM, Cheema F, O’Sullivan DM, Ali A, Ebiogluz L, et al. COVID-19 in solid organ transplant recipients: observations from Connecticut. Transplantation. 2021;105:e6–8.
104. Gupta A, Kute VB, Patel HV, Engineer DP, Banerjee S, Modi PR, et al. Feasibility of convalescent plasma therapy in kidney transplant recipients with severe COVID-19: a single-center prospective cohort study. Exp Clin Transplant. 2021;19:304–9.
105. Rodionov RN, Biener A, Spiehl P, Achleitner M, Holig K, Aringer M, et al. Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19. Lancet Microbe. 2021;2:e138.
106. Joyner MJ, Senefeld JW, Klassen SA, Mills JR, Johnson PW, Theel ES, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience. medRxiv. 2020. https://doi.org/10.1101/2020.08.12.20169359.
107. Casadevall A, Henderson JP, Joyner MJ, Pirofiski LA. SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities. J Clin Invest. 2021;131(7):e148832.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Senefeld JW, Klassen SA, Ford SK, et al. Use of convalescent plasma in COVID-19 patients with immunosuppression. Transfusion. 2021;1–9. https://doi.org/10.1111/trf.16525